Loading clinical trials...
Loading clinical trials...
A Randomized, Placebo-Controlled, Double-Blind, Phase I Study to Evaluate the Safety and Bridging Pharmacokinetics Profile of FB825 for Single Subcutaneous Administration in Healthy Adults
Conditions
Interventions
FB825 or Placebo in subcutaneous route
FB825 in intravenous route
Locations
1
United States
Phase I center
Anaheim, California, United States
Start Date
May 3, 2023
Primary Completion Date
March 26, 2024
Completion Date
March 26, 2024
Last Updated
January 26, 2024
NCT07262983
NCT06389136
NCT06342713
NCT07223697
NCT07290803
NCT07265479
Lead Sponsor
Oneness Biotech Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions